海翔药业(002099.SZ)：与万邦德制药签订《创新药合作协议》

Core Viewpoint - Haisheng Pharmaceutical (002099.SZ) has signed an "Innovative Drug Cooperation Agreement" with Wanbangde Pharmaceutical Holdings Group Co., Ltd., focusing on collaboration for the treatment of amyotrophic lateral sclerosis (ALS) [1] Group 1 - The initial collaboration will concentrate on the development and commercialization of the orphan drug WP205, which has already received orphan drug designation from regulatory authorities [1] - Future cooperation will also include the development of small molecule cyclic peptide agonists targeting melanocortin receptors (MCR) [1]